Article Versions Notes

Liguori L, Luciano A, Polcaro G, Ottaiano A, Cascella M, Perri F, Pepe S, Sabbatino F. Prior Anti-Angiogenic TKI-Based Treatment as Potential Predisposing Factor to Nivolumab-Mediated Recurrent Thyroid Disorder Adverse Events in mRCC Patients: A Case Series. Biomedicines. 2023; 11(11):2974. https://doi.org/10.3390/biomedicines11112974

Liguori, Luigi, Angelo Luciano, Giovanna Polcaro, Alessandro Ottaiano, Marco Cascella, Francesco Perri, Stefano Pepe, and Francesco Sabbatino. 2023. "Prior Anti-Angiogenic TKI-Based Treatment as Potential Predisposing Factor to Nivolumab-Mediated Recurrent Thyroid Disorder Adverse Events in mRCC Patients: A Case Series" Biomedicines 11, no. 11: 2974. https://doi.org/10.3390/biomedicines11112974

Liguori, L., Luciano, A., Polcaro, G., Ottaiano, A., Cascella, M., Perri, F., Pepe, S., & Sabbatino, F. (2023). Prior Anti-Angiogenic TKI-Based Treatment as Potential Predisposing Factor to Nivolumab-Mediated Recurrent Thyroid Disorder Adverse Events in mRCC Patients: A Case Series. Biomedicines, 11(11), 2974. https://doi.org/10.3390/biomedicines11112974